Westpac Banking Corporation (WBC) Earnings power underrated

March 28, 2024

Westpac Banking Corporation is the third - largest of the big four commercial banks by market capitalisation and offers a full suite of financial services to more than 13 million customers. Westpac’s first - quarter FY24 profit of $1.8 billion was little changed from the final quarter of FY23, with interest margin pressure and higher bad debts well managed. Despite some modest pricing changes recently, headwinds from customer deposit price competition and switching and home loan discounting, persist and are expected to see margins ease further in 2024. Concerns about Westpac’s ability to compete should be subsiding though, as the bank is now growing deposits and home loans in line with the market, in fact, even growing ahead of the market in the six months to December 2023. Bad debt expenses a share of loans increased 3 basis points to 0.10%, below our FY24 forecast of 0.12%, and medium - term expectation of 0.17%. With credit stress rising from low levels, it is likely bad debts have bottomed, but the bank is sitting on large provision balances which will help soften the impact on earnings.

As margins shrink and bad debts creep higher, earnings growth will be challenging for the Australian banks in the short term, but the current share price paints too bleak a picture on the medium-term earnings power of Westpac, in our view. Over the next five years, we assume rational competition returns for pricing loans and customer deposits. As the second-largest lender and deposit holder, Westpac should be a willing participant as it stands to benefit materially. Most Australian banks, excluding Commonwealth Bank, face single digit return on equity in FY24, compared with our assumed 9% cost of equity, supporting our view that current loan and deposit price competition is unlikely to persist indefinitely. Shares in Westpac are undervalued compared with our unchanged $28 fair value estimate.

Insights that count

Discover the best opportunities to outperform the market. Our research team dig deep into the market, company and stock data to bring you insights others might overlook.

CSL (CSL) - Vifor challenges

CSL engages in the research, development, manufacture, marketing and distribution of biopharmaceutical products, principally plasma-derived treatments from its Behring division, nephrology therapies from its Vifor business, and vaccines from its Seqirus division

Learn More

Wesfarmers (WES) - AI-ming high

Wesfarmers is a retail and industrial conglomerate that owns the Bunnings hardware chain, Kmart discount department stores and Officeworks supplies chain, and the Wesfarmers chemicals, energy and fertiliser (WESCEF) business.

Learn More

Steadfast Group (SDF) – Take the Money

Steadfast Group Limited provides general insurance brokerage services in Australasia, Asia, and Europe.

Learn More

Want to keep up to
date on our latest news & insights

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.